Candidiasis (Candidosis)
Candidiasis (Candidosis)
Candidiasis (Candidosis)
Candida albicans and other Candida species are fungal infections commonly
involved in human disease. Clinical disease may be as varied as
mucocutaneous infections, chronic mucocutaneous candidiasis, candidemia
and sepsis, and invasive infections of internal organs. The mortality rate for
invasive candidal disease is high, estimated to range from 20-40% in children,
particularly preterm infants. Mortality is also high among the elderly,
especially when other comorbid conditions are present.
Extensive cutaneous
candidiasis in a preterm
infant
This presentation can occur at any age but is mainly seen in pregnant
women, those with intrauterine devices, and in women taking oral
contraceptives. Other associations include diabetes, obesity, and
corticosteroid use. It is characterized by erythema of the vulvar and
vaginal mucosa, leucorrhea, and itching.
Balanit
1. Increased colonization.
2. Breakdown of normal mucosal, skin, or epithelial barrier.
3. Loss of immune mechanisms responsible for preventing candidemia and
invasion to deeper tissues.
Treatment Options
Careful handling of intravenous catheters, careful use of antimicrobial agents, and prompt
removal of infected devices should be performed when possible. Fluconazole prophylaxis has
been used with good results in preventing invasive disease in extremely low birth weight infants.
In cutaneous or mucosal candidiasis, topical antifungal agents are usually adequate. A topical
imidazole (e.g., ketoconazole gel or cream, oxiconazole cream, ketoconazole cream) applied
twice daily is generally effective in treating intertrigo. Ketoconazole should be avoided in the
diaper area due to concerns of systemic absorption.
Nystatin oral suspension (100,000 U/ml - 1 ml swish and spit 4 times a day) or 100,000-unit
pastille for 7-14 days is effective for oral candidal infections. Amphotericin lozenges (10mg) or
suspension (100mg/ml) 4 times a day for 14-21 days is effective as well. Miconazole gel 2% 2.5
ml applied topically 4 times a day for 14-21 days is also a treatment option.
For paronychia and onychia, systemic treatment should be used. Effective
regimens include: itraconazole 200 mg daily for 3 months or 200 mg BID for 1
week each month for 3 months and fluconazole 150-300 mg weekly in adults
or 1-2 mg/kg weekly in children for 4-6 weeks. Topical treatments with
topical azoles, such as efinaconazole and tavaborole, can be attempted in
children and adults who cannot take systemic antifungals.